ONCY 8-K SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

ONCY ▲ +30.86% at T+5d

NEUTRAL call ✓ call won +30.86% · α vs SPY +29.19% · entry $0.8100 → $1.06

Next anchor: T+20d in 16d

Last close $0.8400 (close Jun 5) · +3.70% from $0.8100 entry

Entry anchored
May 21, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α -0.59%

$0.8100

settled 12d ago

T+5d

+30.86%

call +30.86% · α +29.19%

$1.06

settled 6d ago

T+20d

—

call — · α —

—

in 16d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2026, showing pelareorep activates innate and adaptive immune responses and expands mutant KRAS-specific T cells. The press release contains no new financial information or definitive clinical outcomes, making this a routine scientific update.

Actionable Insight

Monitor ASCO presentation on May 30 for any additional data or commentary that could move the stock. Without new efficacy or safety endpoints, this filing is unlikely to be a near-term catalyst.

Key Facts

Data will be presented at ASCO 2026 (May 29-June 2) on pelareorep's mechanism of action.
Translational analyses show pelareorep induces antiviral and anti-tumor immune responses.
Expansion of mutant KRAS-specific T cell clones correlated with tumor volume reduction in pancreatic cancer.
AWARE-1 breast cancer biopsies showed increased CXCL13 and tertiary lymphoid structure formation.
No financial figures, guidance, or clinical endpoints were disclosed.

Financial Impact

No financial impact reported.

Risk Factors

Translational data may not translate into clinical efficacy in ongoing trials.
No update on cash runway or regulatory milestones.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

75% bullish (8 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001129928-26-000035
Document: asco2026pressrelease.htm	0001129928-26-000035
Document: 0001129928-26-000035-index-headers.html	0001129928-26-000035
Document: 0001129928-26-000035-index.html	0001129928-26-000035
Document: 0001129928-26-000035.txt	0001129928-26-000035

11 reports for ONCY

T+1T+5T+20T+60

57% Hit rate 4 of 7 directional calls best @ T+5▲ +10.53%Apr 6, 2026

Filters

Reports for ONCY — sortable, filterable
	Type				Now
Jun 2, 2026 4d ago	8-K NEUTRAL ★ 2/10	$0.9300 $0.8800	▼ −5.38%	▼ −4.68%	$0.8400 (−9.68%)
Jun 1, 2026 5d ago	8-K NEUTRAL ★ 3/10	$1.06 $0.9300	▼ −12.26%	▼ −12.41%	$0.8400 (−20.75%)
May 22, 2026 15d ago	8-K NEUTRAL ★ 3/10	$0.8100 $0.8100	· 0.00%	▼ −0.59%	$0.8400 (+3.70%)
May 22, 2026 15d ago	Press Release NEUTRAL ★ 4/10	$0.8100 $0.8100	· 0.00%	▼ −0.59%	$0.8400 (+3.70%)
Apr 27, 2026 5w ago	8-K BULLISH ★ 7/10	$0.9700 $0.9000	▼ −7.22%	▼ −6.73%	$0.8400 (−13.40%)
Apr 6, 2026 8w ago	424B5 BEARISH ★ 6/10	$0.9000 $0.9100	▼ −1.11%	▲ +1.43%	$0.8400 (+6.67%)
Apr 6, 2026 8w ago	8-K BULLISH ★ 6/10	$0.9500 $0.9000	▼ −5.26%	▼ −5.33%	$0.8400 (−11.58%)
Apr 6, 2026 8w ago	EFFECT BEARISH ★ 6/10	$0.9500 $0.9000	▲ +5.26%	▲ +5.33%	$0.8400 (+11.58%)
Apr 1, 2026 9w ago	S-3 BEARISH ★ 6/10	$0.9300 $0.9600	▼ −3.23%	▼ −3.15%	$0.8400 (+9.68%)
Mar 11, 2026 12w ago	Insider Cluster BULLISH ★ 5/10	$1.01 $0.9600	▼ −4.95%	▼ −3.47%	$0.8400 (−16.83%)

US Market Status

Market Closed — Opens Mon (12h 3m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access